Q-omics provides the consensus-scored GAPDHP26 profile across patient tissues and cancer cell-line models. GAPDHP26 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GAPDHP26 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, GAPDHP26 RNA expression shows 5,814 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, LUSC, and STAD as cancer lineages where GAPDHP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP26 survival associations across molecular data types. GAPDHP26 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP26 RNA expression–survival associations across cancer types. High GAPDHP26 expression shows unfavorable associations in KICH, DLBC, TGCT, UVM and OV, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify KIRP as the clearest survival context for GAPDHP26 RNA expression.
This table summarizes GAPDHP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP26 shows higher tumor expression in LUSC, HNSC, LUAD, UCEC and KIRC. The LUSC box plot shows higher GAPDHP26 RNA expression in tumor versus normal tissue (log2 FC = +0.031, t-test p < 0.001).
This table shows molecular features associated with GAPDHP26 in patient tissues and cancer cell lines. In patient samples, GAPDHP26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
